Soaring drug prices continue to be a big problem for the US pharmaceutical market as manufacturers continue to look for ways to offset patent expiration sale losses and to quickly monetize newly approved medicines. The prices of about 60 brand-name prescription drugs have more than doubled and prices have at least quadrupled for about 20 since December 2014. In the second quarter of 2015, drug prices rose by more than 12% and, with pricing issues becoming become an issue in the 2016 presidential candidates, the sector is expected to see major changes to tax laws and price regulations. It does not appear, unfortunately, that the problems will abate any time soon. Based on Mergent’s analysis, spending on drugs is expected to increase up to more than US$600 billion based on invoice prices by 2020. #MergentInc #industryreports #pharmaceuticals
Full material is published in the Mergent Industry Reports
Industry Reports Blog
Highlighting some of the latest industry analysis from our research desk
The Industry Reports are sold as a subscription throughout the United States, Canada, Japan, Australia and Europe. To request a full sample report please complete the the form here.
Blog Post Categories
Get updates on the latest industry news and trends via an RSS feed to your website